Q32 Bio (NASDAQ:QTTB) Upgraded by Zacks Research to “Strong-Buy” Rating

Q32 Bio (NASDAQ:QTTB) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

QTTB has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Q32 Bio in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Q32 Bio has an average rating of “Moderate Buy” and an average price target of $13.00.

Q32 Bio Stock Performance

Shares of Q32 Bio stock opened at $6.82 on Thursday. Q32 Bio has a 12 month low of $1.35 and a 12 month high of $7.80. The firm has a market capitalization of $83.89 million, a P/E ratio of 2.97 and a beta of 0.14. The company has a current ratio of 4.85, a quick ratio of 4.57 and a debt-to-equity ratio of 0.08. The business has a fifty day simple moving average of $4.29 and a two-hundred day simple moving average of $3.15.

Q32 Bio (NASDAQ:QTTB) last released its earnings results on Tuesday, March 10th. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $4.71. The business had revenue of $53.74 million during the quarter. On average, equities analysts forecast that Q32 Bio will post -12.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Q32 Bio news, CEO Jodie Pope Morrison sold 9,896 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $44,630.96. Following the completion of the sale, the chief executive officer directly owned 89,104 shares in the company, valued at approximately $401,859.04. This trade represents a 10.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 16,706 shares of company stock worth $75,344. Corporate insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in QTTB. Opaleye Management Inc. bought a new stake in shares of Q32 Bio during the fourth quarter valued at approximately $708,000. Geode Capital Management LLC boosted its stake in Q32 Bio by 19.9% during the 4th quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock valued at $352,000 after purchasing an additional 17,617 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Q32 Bio by 110.6% in the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after purchasing an additional 52,300 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Q32 Bio in the fourth quarter worth $84,000. Finally, HRT Financial LP lifted its holdings in shares of Q32 Bio by 66.5% during the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after purchasing an additional 9,862 shares in the last quarter. Institutional investors own 31.32% of the company’s stock.

Key Stories Impacting Q32 Bio

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright raised multi-year EPS forecasts and reiterated a Buy rating with a $13 price target, trimming losses in near-term years and projecting positive earnings by FY2029–FY2030 (FY2029 $0.16; FY2030 $0.41). This institutional upgrade and target amplify upside expectations.
• Positive Sentiment: Zacks added QTTB to its Rank #1 (Strong Buy) momentum lists on March 13, highlighting renewed buy-side interest and momentum flow into the stock. Best Momentum Stocks to Buy for March 13th
• Positive Sentiment: Zacks also listed QTTB among new Strong Buy additions on March 13, reinforcing short-term analyst-driven demand. New Strong Buy Stocks for March 13th
• Neutral Sentiment: Zacks highlights that analysts’ price targets imply a ~103.6% upside vs. the current level — a bullish headline, but the story notes such consensus upside metrics can be unreliable and should be weighed against operational and clinical risk. Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
• Neutral Sentiment: There’s press coverage on HC Wainwright’s Q1 earnings outlook for Q32 Bio; details may influence near-term expectations once parsed by investors. What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings?
• Negative Sentiment: Despite the analyst upgrades, the sell-side consensus for the current fiscal year remains deeply negative (consensus ~-12.32 EPS), keeping fundamental downside risk and valuation uncertainty elevated — a key reason some investors are selling into rallies.
• Negative Sentiment: Short-term volatility risk remains after the company’s recent unusual EPS print (reported EPS of $3.65 on March 10) and the disparity between that beat and long-term consensus; such divergence can trigger profit-taking and skepticism until guidance/continuity is clear.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.